Roger D Kouyos1, Andri Rauch2, Jürg Böni2, Sabine Yerly2, Cyril Shah2, Vincent Aubert2, Thomas Klimkait2, Helen Kovari2, Alexandra Calmy2, Matthias Cavassini2, Manuel Battegay2, Pietro L Vernazza2, Enos Bernasconi2, Bruno Ledergerber2, Huldrych F Günthard2. 1. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland, Institute of Medical Virology, University of Zurich, Zurich, Switzerland, Laboratory of Virology, University Hospital Geneva, Geneva, Switzerland, Division of Immunology and Allergy, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland, Department Biomedicine, University of Basel, Basel, Switzerland, Division of Infectious Diseases, Geneva University Hospital, Geneva, Division of Immunology, University Hospital Lausanne, Lausanne, Switzerland, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Division of Infectious Diseases, Cantonal Hospital St Gallen, St Gallen, Switzerland and Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland roger.kouyos@uzh.ch. 2. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland, Institute of Medical Virology, University of Zurich, Zurich, Switzerland, Laboratory of Virology, University Hospital Geneva, Geneva, Switzerland, Division of Immunology and Allergy, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland, Department Biomedicine, University of Basel, Basel, Switzerland, Division of Infectious Diseases, Geneva University Hospital, Geneva, Division of Immunology, University Hospital Lausanne, Lausanne, Switzerland, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Division of Infectious Diseases, Cantonal Hospital St Gallen, St Gallen, Switzerland and Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland.
Abstract
BACKGROUND: HCV coinfection remains a major cause of morbidity and mortality among HIV-infected individuals and its incidence has increased dramatically in HIV-infected men who have sex with men(MSM). METHODS: Hepatitis C virus (HCV) coinfection in the Swiss HIV Cohort Study(SHCS) was studied by combining clinical data with HIV-1 pol-sequences from the SHCS Drug Resistance Database(DRDB). We inferred maximum-likelihood phylogenetic trees, determined Swiss HIV-transmission pairs as monophyletic patient pairs, and then considered the distribution of HCV on those pairs. RESULTS: Among the 9748 patients in the SHCS-DRDB with known HCV status, 2768(28%) were HCV-positive. Focusing on subtype B(7644 patients), we identified 1555 potential HIV-1 transmission pairs. There, we found that, even after controlling for transmission group, calendar year, age and sex, the odds for an HCV coinfection were increased by an odds ratio (OR) of 3.2 [95% confidence interval (CI) 2.2, 4.7) if a patient clustered with another HCV-positive case. This strong association persisted if transmission groups of intravenous drug users (IDUs), MSMs and heterosexuals (HETs) were considered separately(in all cases OR>2). Finally we found that HCV incidence was increased by a hazard ratio of 2.1 (1.1, 3.8) for individuals paired with an HCV-positive partner. CONCLUSIONS: Patients whose HIV virus is closely related to the HIV virus of HIV/HCV-coinfected patients have a higher risk for carrying or acquiring HCV themselves. This indicates the occurrence of domestic and sexual HCV transmission and allows the identification of patients with a high HCV-infection risk.
BACKGROUND:HCV coinfection remains a major cause of morbidity and mortality among HIV-infected individuals and its incidence has increased dramatically in HIV-infectedmen who have sex with men(MSM). METHODS:Hepatitis C virus (HCV) coinfection in the Swiss HIV Cohort Study(SHCS) was studied by combining clinical data with HIV-1 pol-sequences from the SHCS Drug Resistance Database(DRDB). We inferred maximum-likelihood phylogenetic trees, determined Swiss HIV-transmission pairs as monophyletic patient pairs, and then considered the distribution of HCV on those pairs. RESULTS: Among the 9748 patients in the SHCS-DRDB with known HCV status, 2768(28%) were HCV-positive. Focusing on subtype B(7644 patients), we identified 1555 potential HIV-1 transmission pairs. There, we found that, even after controlling for transmission group, calendar year, age and sex, the odds for an HCV coinfection were increased by an odds ratio (OR) of 3.2 [95% confidence interval (CI) 2.2, 4.7) if a patient clustered with another HCV-positive case. This strong association persisted if transmission groups of intravenous drug users (IDUs), MSMs and heterosexuals (HETs) were considered separately(in all cases OR>2). Finally we found that HCV incidence was increased by a hazard ratio of 2.1 (1.1, 3.8) for individuals paired with an HCV-positive partner. CONCLUSIONS:Patients whose HIV virus is closely related to the HIV virus of HIV/HCV-coinfectedpatients have a higher risk for carrying or acquiring HCV themselves. This indicates the occurrence of domestic and sexual HCV transmission and allows the identification of patients with a high HCV-infection risk.
Authors: Elizabeth Wolf; Joshua T Herbeck; Stephen Van Rompaey; Mari Kitahata; Katherine Thomas; Gregory Pepper; Lisa Frenkel Journal: AIDS Res Hum Retroviruses Date: 2016-11-01 Impact factor: 2.205
Authors: Roger D Kouyos; Barbara Hasse; Alexandra Calmy; Matthias Cavassini; Hansjakob Furrer; Marcel Stöckle; Pietro L Vernazza; Enos Bernasconi; Rainer Weber; Huldrych F Günthard; V Aubert; M Battegay; E Bernasconi; J Böni; H C Bucher; C Burton-Jeangros; A Calmy; M Cavassini; G Dollenmaier; M Egger; L Elzi; J Fehr; J Fellay; H Furrer; C A Fux; M Gorgievski; H Günthard; D Haerry; B Hasse; H H Hirsch; M Hoffmann; I Hösli; C Kahlert; L Kaiser; O Keiser; T Klimkait; R Kouyos; H Kovari; B Ledergerber; G Martinetti; B Martinez de Tejada; K Metzner; N Müller; D Nadal; D Nicca; G Pantaleo; A Rauch; S Regenass; M Rickenbach; C Rudin; F Schöni-Affolter; P Schmid; J Schüpbach; R Speck; P Tarr; A Trkola; P Vernazza; R Weber; S Yerly Journal: Open Forum Infect Dis Date: 2015-06-03 Impact factor: 3.835
Authors: Karin Neukam; Pompeyo Viciana; Guillermo Ojeda-Burgos; Marcial Delgado-Fernández; María J Ríos; Juan Macías; Dolores Merino; Antonio Collado; Francisco Téllez; Juan A Pineda Journal: BMC Infect Dis Date: 2016-09-15 Impact factor: 3.090
Authors: Bernadien M Nijmeijer; Ramin Sarrami-Forooshani; Gaby S Steba; Renée Rce Schreurs; Sylvie M Koekkoek; Richard Molenkamp; Janke Schinkel; Peter Reiss; Matthijs L Siegenbeek van Heukelom; Marc van der Valk; Carla Ms Ribeiro; Teunis Bh Geijtenbeek Journal: J Int AIDS Soc Date: 2019-03 Impact factor: 5.396
Authors: Parastu Kasaie; Barun Mathema; W David Kelton; Andrew S Azman; Jeff Pennington; David W Dowdy Journal: PLoS One Date: 2015-12-17 Impact factor: 3.240
Authors: Frederic Bertels; Alex Marzel; Gabriel Leventhal; Venelin Mitov; Jacques Fellay; Huldrych F Günthard; Jürg Böni; Sabine Yerly; Thomas Klimkait; Vincent Aubert; Manuel Battegay; Andri Rauch; Matthias Cavassini; Alexandra Calmy; Enos Bernasconi; Patrick Schmid; Alexandra U Scherrer; Viktor Müller; Sebastian Bonhoeffer; Roger Kouyos; Roland R Regoes Journal: Mol Biol Evol Date: 2018-01-01 Impact factor: 16.240